Belldegrun A - Search Results

1

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.

Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Cangiano T, et al. Among authors: belldegrun a. J Clin Oncol. 1999 Feb;17(2):523-8. doi: 10.1200/JCO.1999.17.2.523. J Clin Oncol. 1999. PMID: 10080595

2

Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study.

Litwin MS, Fine JT, Dorey F, Figlin RA, Belldegrun AS. Litwin MS, et al. Among authors: belldegrun as. J Urol. 1997 May;157(5):1608-12. J Urol. 1997. PMID: 9112487

3

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.

Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Figlin RA, et al. Among authors: belldegrun as. J Clin Oncol. 1999 Aug;17(8):2521-9. doi: 10.1200/JCO.1999.17.8.2521. J Clin Oncol. 1999. PMID: 10561318 Clinical Trial.

4

Improved prognostication of renal cell carcinoma using an integrated staging system.

Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: belldegrun as. J Clin Oncol. 2001 Mar 15;19(6):1649-57. doi: 10.1200/JCO.2001.19.6.1649. J Clin Oncol. 2001. PMID: 11250993

5

Vaccine and gene therapy of renal cell carcinoma.

Gitlitz BJ, Belldegrun AS, Figlin RA. Gitlitz BJ, et al. Among authors: belldegrun as. Semin Urol Oncol. 2001 May;19(2):141-7. Semin Urol Oncol. 2001. PMID: 11354534 Review.

6

Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome.

Zisman A, Pantuck AJ, Chao D, Dorey F, Said JW, Gitlitz BJ, de Kernion JB, Figlin RA, Belldegrun AS. Zisman A, et al. Among authors: belldegrun as. J Urol. 2001 Jul;166(1):54-8. J Urol. 2001. PMID: 11435822

7

Dendritic cell-based immunotherapy of renal cell carcinoma.

Gitlitz BJ, Figlin RA, Pantuck AJ, Belldegrun AS. Gitlitz BJ, et al. Among authors: belldegrun as. Curr Urol Rep. 2001 Feb;2(1):46-52. doi: 10.1007/s11934-001-0025-9. Curr Urol Rep. 2001. PMID: 12084295 Review.

8

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion J. Figlin RA, et al. Among authors: belldegrun a. J Clin Oncol. 1992 Mar;10(3):414-21. doi: 10.1200/JCO.1992.10.3.414. J Clin Oncol. 1992. PMID: 1482425 Clinical Trial.

9

Immunotherapy for renal cell carcinoma.

Belldegrun A, Figlin R, Danella J, deKernion J. Belldegrun A, et al. Semin Urol. 1992 Feb;10(1):23-7. Semin Urol. 1992. PMID: 1565900 Review.

10

The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.

Figlin RA, Abi-Aad AS, Belldegrun A, deKernion JB. Figlin RA, et al. Among authors: belldegrun a. Semin Oncol. 1991 Oct;18(5 Suppl 7):102-7. Semin Oncol. 1991. PMID: 1719641 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

422 results

Search Page

Filters